Notably, vaccine strategies targeting wild type (WT) p53 have not reported damage to normal tissues[16, 17] and high-copy numbers of WT p53 peptide-MHC class I complexes were detected on tumour cells as compared to low copies on normal cells.[18–20] Therefore, to maximise applicability and avoid the necessity for mutation screening in clinical applications, we focussed our efforts on raising antibodies to peptides derived from WT p53. This evidence concerns the gene TP53 and neoplasm.